Modulation of biomarkers in minimal breast carcinoma: A model for human breast carcinoma progression

Cancer

Volumn 83, Issue 1, 1998, Pages 89-97

  Querzoli, Patrizia ^a,c   Albonico, Giuseppe ^a   Ferretti, Stefano ^a   Rinaldi, Rosa ^a   Beccati, Donatella ^a   Corcione, Stefano ^b   Indelli, Monica ^b   Nenci, Italo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^c Dipartimento di Morfologia ed Embriologia   (Italy)

Author keywords

Age groups; Estrogen receptor; Menopausal status; Minimal breast carcinoma; Neu; Overall survival; P53; Progesterone receptor; Proliferation index; Relapse free interval

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CARCINOMA IN SITU; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; CELL DIVISION; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032126540     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980701)83:1<89::AID-CNCR12>3.0.CO;2-8     Document Type: Article

References (44)

1. Hartmann WH. Minimal breast cancer. An update. Cancer 1984;53:681-4.
2. Gallager HS, Martin JE. An orientation to the concept of minimal breast cancer. Cancer 1971;28:1505-7.
3. Rajakariar R, Walker RA. Pathological and biological features of mammographically detected invasive breast carcinomas. Br J Cancer 1995;71:150-4.
4. Ciatto S, Rosselli Del Turco M, Bonardi R, Cataliotti L, Distante V, Cadorna G, et al. Non-palpable lesions of the breast detected by mammography - review of 1182 consecutive confirmed cases. Eur J Cancer 1994;1:40-4.
5. Weiss HA, Brinton LA, Brogan D, Coates RJ, Gammon MD, Malone KE, et al. Epidemiology of in situ and invasive breast cancer in women aged under 45. Br J Cancer 1996;73:1298-305.
6. Page DL, Simpson JF. Pathology of preinvasive and excellent-prognosis breast cancer. Curr Opin Oncol 1994;6:549-53.
7. Fentiman IS, Hyland D, Chaudary MA, Gregory WM. Prognosis of patients with breast cancers up to 1 cm in diameter. Eur J Cancer 1996;32A:417-20.
8. Sobin LH, Wittekind C, editors. UICC/TNM classifications of malignant tumors, 5th edition. New York: Wiley-Liss, Inc., 1997.
9. World Health Organization. Histological typing of breast tumors. 2nd ed. Geneva: World Health Organization, 1981.
10. Schnitt SJ, Connolly JL, Harris JR, Hellman S, Cohen RB. Pathologic predictors of early local recurrence in Stage I and II breast cancer treated by primary radiation therapy. Cancer 1984;53:1049-57.
11. Schnitt SJ, Connolly JL. Processing and evaluation of breast excision specimens. Am J Clin Pathol 1992;88:125-37.
12. Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of breast carcinoma. Hum Pathol 1996;27:220-4.
13. Bacus JW, Grace LJ. Optical microscope system for standardized cell measurements and analyses. Appl Optics 1987; 26:3280-93.
14. Bacus SS, Ruby SG, Weinberg DS, Chin D, Ortiz R, Bacus JW. Her-2/neu oncogene expression, DNA ploidy and proliferation index in breast cancers. Am J Pathol 1990;137:103-11.
15. Albonico G, Querzoli P, Ferretti S, Magri E, Nenci I. Biophenotypes of breast carcinoma in situ defined by image analysis of biological parameters. Pathol Res Pract 1996;192:117-23.
16. Querzoli P, Ferretti S, Albonico G, Magri E, Scapoli D, Indelli M, et al. Application of quantitative analysis to biologic profile evaluation in breast cancer. Cancer 1995;76:2510-7.
17. Esteban JM, Chul A, Battifora H, Felder B. Predictive value of estrogen receptors evaluated by quantitative immunohistochemical analysis in breast cancer. Am J Clin Pathol 1994; 102:9-12.
18. Querzoli P, Albonico G, Ferretti S, Rinaldi R, Magri E, Indelli M, et al. MIB-1 proliferative activity in invasive breast cancers measured by image analysis. J Clin Pathol 1996;49:926-30.
19. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappeletti V, et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 1993;85:965-70.
20. Lee E, Desu M. A computer program for comparing k samples with right censored data. Comp Progr Biomed 1972;2: 315-21.
21. Sickles EA. Mammographic features of 300 consecutive non-palpable breast cancers. AJR 1986;146:661-3.
22. Azavedo E, Svane G, Auer G. Stereotactic fine needle biopsy in 2594 mammographically detected nonpalpable lesions. Lancet 1989;12:1033-6.
23. Moezzi M, Melamed I, Vamvakas E, Inghirami G, Mitnick J, Quish A, et al. Morphological and biological characteristics of mammogram-detected invasive breast cancer. Hum Pathol 1996;27:944-8.
24. Arnesson LG, Smeds S, Hatschek, Nordenskjold B, Fagerberg G. Hormone receptors, ploidy and proliferation rate in breast cancers up to 10 mm. Eur J Surg Oncol 1992;18:235-40.
25. Rounanet P, Charlier C, Pujol H. Is there now a consensus on the treatment of minimal breast cancer? In: F. Calvo, M. Crepin, H. Magdelenat, editors. Breast cancer. Advances in biology and therapeutics. John Libbey Eurotext, 1996;97.
26. Sinn HP, Oelmann A, Anton HW, Diel IJ. Metastatic potential of small and minimally invasive breast carcinomas. Virchow's Arch 1994;425:237-41.
27. Moriya T, Silverberg SG. Intraductal carcinoma (ductal carcinoma in situ) of the breast. A comparison of pure non-invasive tumors with those including different proportions of infiltrating carcinoma. Cancer 1994;74:2972-8.
28. Leitner SP, Swern AS, Weinberger D, Duncan LJ, Hutter RVP. Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1 a,b N0M0). Cancer 1995;76:2266-74.
29. Allred CD, O'Connell P, Fuqua SAW, Osborne CK. Immunohistochemical studies of early breast cancer evolution. Breast Cancer Res Treat 1994;32:13-8.
30. Goldhirsch A, Wood WC, Senn HJ, Click JH, Gelber RD. International Consensus Panel on the Treatment of Primary Breast Cancer. Eur J Cancer 1995;31A:1754-9.
31. Schmitt FC, Figueiredo P, Lacerda M. Expression of c-erb B-2 protein and DNA ploidy in breast carcinogenesis. Arch Pathol Lab Med 1995;119:815-20.
32. Bose S, Lesser ML, Norton L, Rosen PP. Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med 1996;120: 81-5.
33. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, et al. Prognostic classification of breast ductal carcinoma in situ. Lancet 1995;345:1154-7.
34. O'Malley FP, Saad Z, Kerkvliet N, Doig G, Stitt L, Ainsworth P, et al. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erbB-2 in lymph node-negative breast cancer. Hum Pathol 1996;27: 955-63.
35. Querzoli P, Albonico G, Ferretti S, Rinaldi R, Nenci I. Biological staging of incipient, in situ, and invasive breast carcinomas. Ann NY Acad Sci 1996;784:381-94.
36. Elledge RM, Allred DC. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 1994;32:39-47.
37. Peer PGM, Verbeek ALM, Mravunac M, Hendriks JHCL, Holland R. Prognosis of younger and older patients with early breast cancer. Br J Cancer 1996;73:382-5.
38. Walker RA, Lees E, Web M, Dearing SJ. Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer 1996;74:1796-800.
39. Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 1996;77:97-103.
40. De La Rochefordiere A, Asselain B, Campana F, Scholl SM, Fentome J, Vilcoq JR, et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993;341:1039-43.
41. Allred DC, Clark GM, Molina R, Tandon AF, Schnitt SJ, Kennedy W, et al. Overexpression of Her-2/Neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992;23:974-9.
42. Barnes DM, Bartkova J, Camplejohn RS, Gullick WJ, Smith SJ, Millis RR. Overexpression of c-erbB-2 Oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer 1992;28(2/3):644-8.
43. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P, et al. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated? Cancer 1994;73: 664-7.
44. Mittra I. Axillary lymph node metastasis in breast cancer: prognostic indicator or lead-time bias? Eur J Cancer 1993; 29A:300-2.